A groundbreaking new study has revealed that a daily pill may soon replace the need for injections of weight-loss drugs like Wegovy and Ozempic. The trial found that this new pill, called Orforglipron, led to significant weight loss and improved blood sugar levels in individuals with obesity and type 2 diabetes.
Orforglipron, developed by pharmaceutical company Eli Lilly, works in a similar way to semaglutide, the active ingredient in Wegovy and Ozempic. This pill mimics a hormone called GLP-1, which plays a key role in regulating blood sugar levels and appetite.
In a prior trial, Orforglipron was shown to help people with obesity lose around 11% of their body weight over 72 weeks. While this is slightly less than the weight loss typically achieved with injectable semaglutide, taking a pill is much more convenient for patients.
To further investigate the potential benefits of Orforglipron for individuals with obesity and type 2 diabetes, researchers conducted a study involving over 1600 participants from 10 different countries. The participants were divided into groups receiving different doses of Orforglipron or a placebo, along with lifestyle advice.
After 72 weeks, the group receiving the highest dose of Orforglipron had lost nearly 10% of their body weight, with significant improvements in blood sugar levels. Even the lower doses of Orforglipron led to meaningful weight loss and better blood sugar control compared to the placebo group.
While Orforglipron may not result in as much weight loss as injectable GLP-1 drugs, it still offers important health benefits. Even a 5% weight loss can lead to improvements in overall health and quality of life, according to experts.
Some participants experienced side effects such as nausea, vomiting, and diarrhea, but these were generally manageable. Eli Lilly is optimistic that Orforglipron will receive FDA approval for the treatment of obesity and type 2 diabetes in the near future.
One of the key advantages of Orforglipron is its affordability and ease of administration compared to injectable drugs. This could make it more accessible to individuals in lower- and middle-income countries where access to expensive weight-loss medications is limited.
Overall, Orforglipron shows great promise as a convenient and effective treatment option for individuals struggling with obesity and type 2 diabetes. Its potential to improve health outcomes and quality of life make it a valuable addition to the existing range of weight-loss medications.
